Published in Am J Physiol Renal Physiol on November 21, 2007
Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev (2009) 2.17
Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int (2009) 1.95
Mice expressing ouabain-sensitive α1-Na,K-ATPase have increased susceptibility to pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol (2010) 1.51
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol (2008) 1.35
Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol Renal Physiol (2009) 1.23
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int (2010) 1.16
Na+/Ca2+ exchange and Na+/K+-ATPase in the heart. J Physiol (2015) 1.06
Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin. Hypertension (2009) 0.99
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) (2011) 0.97
Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. J Am Soc Nephrol (2014) 0.96
Reduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac dysfunction and myocyte apoptosis. J Biol Chem (2012) 0.95
Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim Biophys Acta (2010) 0.94
Molecular mechanisms of experimental salt-sensitive hypertension. J Am Heart Assoc (2012) 0.90
Reactive Oxygen Species Modulation of Na/K-ATPase Regulates Fibrosis and Renal Proximal Tubular Sodium Handling. Int J Nephrol (2012) 0.90
Effects of Na/K-ATPase and its ligands on bone marrow stromal cell differentiation. Stem Cell Res (2014) 0.87
Excisional wound healing is delayed in a murine model of chronic kidney disease. PLoS One (2013) 0.86
Marinobufagenin enhances cardiac contractility in mice with ouabain-sensitive alpha1 Na+-K+-ATPase. Am J Physiol Heart Circ Physiol (2009) 0.84
Reduction of Na/K-ATPase affects cardiac remodeling and increases c-kit cell abundance in partial nephrectomized mice. Am J Physiol Heart Circ Physiol (2014) 0.84
Renal ischemia regulates marinobufagenin release in humans. Hypertension (2010) 0.80
The Trade-Off between Dietary Salt and Cardiovascular Disease; A Role for Na/K-ATPase Signaling? Front Endocrinol (Lausanne) (2014) 0.80
Expression of rat Na-K-ATPase α2 enables ion pumping but not ouabain-induced signaling in α1-deficient porcine renal epithelial cells. Am J Physiol Cell Physiol (2015) 0.78
The Role of Na/K-ATPase Signaling in Oxidative Stress Related to Obesity and Cardiovascular Disease. Molecules (2016) 0.78
p53 negatively regulates the osteogenic differentiation of vascular smooth muscle cells in mice with chronic kidney disease. Cardiovasc J Afr (2012) 0.77
Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. PLoS One (2016) 0.76
Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure. Circ Heart Fail (2015) 0.76
Experimental models of renal disease and the cardiovascular system. Open Cardiovasc Med J (2010) 0.76
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. PLoS One (2017) 0.75
Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy. Sci Rep (2016) 0.75
Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling. J Am Heart Assoc (2016) 0.75
The physiological and clinical importance of sodium potassium ATPase in cardiovascular diseases. Curr Opin Pharmacol (2016) 0.75
Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD). Physiol Rep (2016) 0.75
Cigarette Smoking Causes Epigenetic Changes Associated With Cardiorenal Fibrosis. Physiol Genomics (2016) 0.75
Decreased renal AT1 receptor binding in rats after subtotal nephrectomy: PET study with [(18)F]FPyKYNE-losartan. EJNMMI Res (2016) 0.75
Reducing Cardiac Fibrosis: Na/K-ATPase Signaling Complex as a Novel Target. Cardiovasc Pharm Open Access (2017) 0.75
MicroRNA profiling in kidney disease: Plasma versus plasma-derived exosomes. Gene (2017) 0.75
Some statistical methods useful in circulation research. Circ Res (1980) 11.88
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension (2006) 2.64
Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol (2004) 1.67
Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res (1991) 1.63
Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice. J Physiol (2005) 1.58
Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol Heart Circ Physiol (2004) 1.52
Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension (2006) 1.42
Physiological role of the alpha1- and alpha2-isoforms of the Na+-K+-ATPase and biological significance of their cardiac glycoside binding site. Am J Physiol Regul Integr Comp Physiol (2006) 1.30
Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail (2005) 1.26
Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation (2005) 1.14
A reproducible model for chronic renal failure in the mouse. Urol Res (1983) 1.13
AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens (2006) 1.07
Effect of chronic renal failure on cardiac contractile function, calcium cycling, and gene expression of proteins important for calcium homeostasis in the rat. J Am Soc Nephrol (2003) 1.03
Murine models for the study of congestive heart failure: Implications for understanding molecular mechanisms and for drug discovery. J Pharmacol Toxicol Methods (2004) 0.99
Left ventricular pressure-volume relationship in a murine model of congestive heart failure due to acute viral myocarditis. J Am Coll Cardiol (2002) 0.93
Evaluation of left ventricular function in cardiomyopathic mice by tissue Doppler and color M-mode Doppler echocardiography. Echocardiography (2005) 0.86
Histopathological study of time course changes in inter-renal aortic banding-induced left ventricular hypertrophy of mice. Int J Exp Pathol (2007) 0.83
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA (2004) 9.91
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension (2006) 2.64
Cardiac glycoside downregulates NHE3 activity and expression in LLC-PK1 cells. Am J Physiol Renal Physiol (2005) 2.18
Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. Am J Kidney Dis (2003) 2.18
Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev (2009) 2.17
Platelet dysfunction and end-stage renal disease. Semin Dial (2006) 2.09
First finite element model of the left ventricle with mitral valve: insights into ischemic mitral regurgitation. Ann Thorac Surg (2010) 1.99
Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase. J Biol Chem (2004) 1.71
Identification of a pool of non-pumping Na/K-ATPase. J Biol Chem (2007) 1.69
Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts. Cardiovasc Res (2006) 1.67
ANP differentially modulates marinobufagenin-induced sodium pump inhibition in kidney and aorta. Hypertension (2006) 1.62
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods (2008) 1.60
Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens (2002) 1.56
Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension. J Hypertens (2004) 1.52
Embolic protection and platelet inhibition during renal artery stenting. Circulation (2008) 1.52
Retrospective comparison of surgical treatment modalities in 100 patients with oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2009) 1.51
Src-mediated inter-receptor cross-talk between the Na+/K+-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. J Biol Chem (2002) 1.51
Utility of a 0.014" pressure-sensing guidewire to assess renal artery translesional systolic pressure gradients. Catheter Cardiovasc Interv (2003) 1.49
The Na/K-ATPase/Src complex and cardiotonic steroid-activated protein kinase cascades. Pflugers Arch (2008) 1.46
High salt intake causes adverse fetal programming--vascular effects beyond blood pressure. Nephrol Dial Transplant (2012) 1.46
Endogenous cardiotonic steroids and differential patterns of sodium pump inhibition in NaCl-loaded salt-sensitive and normotensive rats. Am J Hypertens (2009) 1.45
Effects of cardiotonic steroids on dermal collagen synthesis and wound healing. J Appl Physiol (1985) (2008) 1.45
Complete versus partial distal embolic protection during renal artery stenting. Catheter Cardiovasc Interv (2009) 1.44
Hyponatremia: clinical diagnosis and management. Am J Med (2007) 1.43
Overexpressing AtPAP15 enhances phosphorus efficiency in soybean. Plant Physiol (2009) 1.43
Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension (2006) 1.42
Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rat. Kidney Int (2002) 1.41
Functional characterization of Src-interacting Na/K-ATPase using RNA interference assay. J Biol Chem (2006) 1.40
Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol (2011) 1.40
Role of caveolae in signal-transducing function of cardiac Na+/K+-ATPase. Am J Physiol Cell Physiol (2003) 1.39
Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. Kidney Int (2004) 1.37
Na/K-ATPase tethers phospholipase C and IP3 receptor into a calcium-regulatory complex. Mol Biol Cell (2005) 1.36
Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol (2008) 1.35
The Na,K-ATPase receptor complex: its organization and membership. Cell Biochem Biophys (2006) 1.32
Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension. Circulation (2002) 1.30
The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. J Vasc Interv Radiol (2005) 1.28
Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res (2009) 1.27
Impact of preadmission variables on USMLE step 1 and step 2 performance. Adv Health Sci Educ Theory Pract (2007) 1.25
Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol (2009) 1.24
Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol Renal Physiol (2009) 1.23
Molecular epidemiology of measles viruses in China, 1995-2003. Virol J (2007) 1.20
Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension. J Hypertens (2008) 1.19
Ouabain-induced endocytosis of the plasmalemmal Na/K-ATPase in LLC-PK1 cells requires caveolin-1. Kidney Int (2005) 1.19
Changes in sodium pump expression dictate the effects of ouabain on cell growth. J Biol Chem (2009) 1.16
Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int (2005) 1.14
Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol (2005) 1.13
Biochemical and molecular characterization of PvPAP3, a novel purple acid phosphatase isolated from common bean enhancing extracellular ATP utilization. Plant Physiol (2009) 1.12
Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens (2005) 1.12
Principles of management of severe hyponatremia. J Am Heart Assoc (2013) 1.12